Nektar sues Lilly, claiming its interest in biotech’s autoimmune drug ‘waned dramatically’ after buying DermiraDermira
08 Aug 2023
Patent Infringement
Nektar Therapeutics is taking Eli Lilly to court in California, saying the Indianapolis-based drugmaker mishandled data and “executed on a scheme to ensure that REZPEG would never succeed” after it bought another autoimmune drug candidate.
The lawsuit was filed in the US District Court for the Northern District of California on Monday, the same day the San Francisco biotech said Lilly miscalculated data in an eczema trial. Lilly axed their six-year, $400 million pact for the investigational drug, known as rezpegaldesleukin, or rezpeg, in April.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.